Navigation Links
Updated: Teikoku Pharma USA, Inc. and Verde Environmental Technologies, Inc. Announce Licensing Agreement for Pharmaceutical Disposal Technology
Date:9/15/2011

SAN JOSE, Calif., Sept. 15, 2011 /PRNewswire/ -- Teikoku Pharma USA, Inc., ("TPU") is pleased to announce an exclusive license agreement with Verde Environmental Technologies Inc. ("Verde"), a company aimed at developing environmentally responsible solutions for pharmaceutical disposal.  Verde is a privately held company, founded by former executives of TPU and Travanti Pharma, Inc.

Verde obtained rights to develop products, which are designed to adsorb and inactivate the active ingredients in pills, tablets, capsules and topical patches, in a convenient and environmentally responsible manner, based on patented technology developed and owned by TPU.  

"We are very pleased that these new product ideas that were generated from our research led to this important new development, stated TPU CEO, Masahisa Kitagawa.  TPU located in San Jose, California is the US operations of Teikoku Seiyaku Co., Ltd., one of the world's largest manufacturers of medicated patches based in Japan, and its product, Lidoderm, is a leading global brand.

"The products being developed by Verde will address the growing issue of pharmaceutical contamination of groundwater supplies.  By providing an effective means of adsorbing the active ingredients, this will help keep waste pharmaceuticals from appearing in the water supply," stated Verde Chairman and CEO, Dr. Andrew Korey.  "In addition, these developments will provide anti-abuse features, and improved safety, by diminishing the risk of accidental poisoning from active pharmaceuticals disposed in trash."

About Teikoku

Teikoku Pharma USA Inc., a wholly-owned subsidiary of Teikoku Seiyaku Inc. of Japan, is a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain Management and CNS. Teikoku's main product is Lidoderm® (Lidocaine 5% Patch) for PHN, in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe, Mundipharma in South East Asia and SK Pharma for Korea.

For more information about Teikoku Pharma USA, Inc. please visit http://www.teikokuusa.com.

Or

Contact: Francisco Bejar
Director, Business Development
408-501-1804
fbejar@teikokuusa.com

About Verde

Verde Environmental Technologies Inc. is a company aimed at developing environmentally responsible solutions for the growing issues related to pharmaceutical disposal.  Products for pharmaceutical manufacturers, pharmacies, and consumers will incorporate carbon adsorptive technologies to inactivate residual active pharmaceutical ingredients in tablets, capsules, patches, etc., and make them safe for disposal in an environmentally responsible manner. Verde operations are based in Minnesota and California.

For more information about Verde environmental Technologies, Inc. please visit http://www.verdeenvirotech.com.

Or

Contact: Andrew Korey
Ph.D. CEO/Chairman
akorey@verdeenvirotech.com


'/>"/>
SOURCE Teikoku Pharma USA, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. UPDATED: Elsevier Online Opinion Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level
2. Licensing Agreement for Pharmaceutical Disposal Technology Between Teikoku Pharma USA, Inc. and Verde Environmental Technologies Inc.
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
Breaking Medicine Technology:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):